1,623 results on '"DEL PRATO, Stefano"'
Search Results
52. Diabetes and acute bacterial skin and skin structure infections
53. Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs
54. Type 1 diabetes and COVID-19: The “lockdown effect”
55. Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
56. COVID-19 in people with diabetes: understanding the reasons for worse outcomes
57. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery
58. Review of methods for detecting glycemic disorders
59. Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
60. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
61. Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial
62. Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial
63. Diabetes and vascular disease: New therapeutic avenues
64. Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes
65. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy
66. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
67. Altered Visual Plasticity in Morbidly Obese Subjects
68. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
69. Guida pratica alla prevenzione e gestione dell’infezione da COVID-19 nelle persone con diabete
70. How conclusive is the CONCLUDE trial?
71. Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire
72. Treatment with Oral Drugs
73. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L)
74. Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial.
75. Cardio‐renal‐metabolic disease in primary care setting.
76. An Italian MODY family with proband and son carrying variants in GCK and HFN1A: is it a true case of digenic MODY?
77. Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT‐proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC
78. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
79. Characterization of tirzepatide-treated patients achieving HbA1c
80. Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes?
81. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
82. Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study
83. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
84. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
85. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study
86. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
87. Assisted reproductive technology, risk of gestational diabetes, and perinatal outcomes in singleton pregnancies
88. Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients
89. The growing clinical effect of SGLT2 inhibitors
90. EFFECTS OF ALBIGLUTIDE ON TYPES AND NUMBERS OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE IN THE HARMONY OUTCOMES TRIAL
91. Diabetes registries and high-quality diabetes care
92. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP:A clinical consensus statement from the Heart Failure Association of the ESC
93. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
94. Hospital incidental diagnosis of diabetes: A population study
95. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials
96. The IGFBP3/TMEM219 pathway regulates beta cell homeostasis
97. Cover Image
98. New forms of insulin and insulin therapies for the treatment of type 2 diabetes
99. Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke
100. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.